Almac has launched a Next Generation Sequencing (NGS) service, expanding its portfolio of services for the development of personalized medicine. This service provides support for the development of molecular tests for trial enrichment and companion diagnostic development, with a focus on targeted re-sequencing. The NGS platform expands Almac’s current services using microarray, qPCR and IHC.   Professor Paul Harkin, president and managing director of Almac’s Diagnostics business unit and Profess...